To receive future news releases direct to your inbox, subscribe by emailing firstname.lastname@example.org.
Historical news and financial information can also be found at www.sedar.com under the Company’s profile.
Resverlogix Names Michael Sweeney, M.D., as Senior Vice President of Clinical Development
November 3, 2014
RVX-208 Leads to a 77% Relative Risk Reduction of Major Adverse Cardiovascular Events (MACE) in Patients with Diabetes Mellitus
September 2, 2014
RVX-208 Reduces Major Adverse Cardiovascular Events (MACE) Significantly in Patients with Diabetes Mellitus
July 23, 2014
Cleveland Clinic Presents RVX-208 Data at American College of Cardiology (ACC) Conference in Washington DC March 31, 2014
March 31, 2014
Resverlogix Announces Combined RVX-208 findings from SUSTAIN & ASSURE Phase 2b Trials
January 15, 2014